BioCentury
ARTICLE | Top Story

Shire builds on HAE franchise with Dyax takeout

November 3, 2015 1:15 AM UTC

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Dyax Corp. (NASDAQ:DYAX) for $37.30 per share, or $5.9 billion in cash. The price represents a 35% premium to Dyax's close of $27.53 on Oct. 30, the last trading day before the deal was announced.

Dyax shareholders also are eligible for a contingent value right (CVR) worth $4 per share, or $646 million, if FDA approves lead candidate DX-2930 by YE19 to prevent Type I and Type II hereditary angioedema (HAE). ...